TREA

97730282 - CELROSFI

Follow

Information

  • Trademark
  • 97730282
  • Serial Number
    97730282
  • Filing Date
    December 23, 2022
    2 years ago
  • Transaction Date
    September 30, 2024
    4 months ago
  • Status Date
    September 30, 2024
    4 months ago
  • Published for Opposition Date
    February 13, 2024
    12 months ago
  • Location Date
    April 09, 2024
    10 months ago
  • Status Code
    730
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    KOPENSKI, CLAUDIA
  • Attorney Docket Number
    00161757-US
    Attorney Name
    Marilyn F. Kelly
    Law Office Assigned Location Code
    O20
  • Owners
Information
Mark Drawing Code
4
Mark Identification
CELROSFI
Case File Statements
  • GS0051: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Case File Event Statements
  • 9/26/2023 - a year ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 12/27/2022 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 12/29/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 9/23/2023 - a year ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/26/2023 - a year ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/26/2023 - a year ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 12/14/2023 - a year ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/14/2023 - a year ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/15/2023 - a year ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/13/2024 - 12 months ago
    12 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/8/2024 - a year ago
    10 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/24/2024 - a year ago
    11 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 2/13/2024 - 12 months ago
    13 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 4/9/2024 - 10 months ago
    14 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 9/30/2024 - 4 months ago
    15 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 9/30/2024 - 4 months ago
    18 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 9/30/2024 - 4 months ago
    16 - SOU EXTENSION 1 FILED Type: EXT1
  • 9/30/2024 - 4 months ago
    17 - SOU EXTENSION 1 GRANTED Type: EX1G